HOME >> MEDICINE >> NEWS
Fighting inflammation with targeted liposomal therapy

Vascular endothelial cells (VECs) form the walls of blood vessels and play a critical role in inflammation. In rheumatoid arthritis (RA), VECs interact with cytokines, proteins that regulate immune response, and allow inflammation to persist, escalate, and progressively damage tissue, and joints. Recognized as potent inflammation inhibitors, corticosteroids work to control the expression of cytokines, adhesion molecules and the growth of endothelial cells. The potential of these drugs, however, has been restricted by their considerable toxicity and short half-life.

To study the impact of corticosteroids on VEC activity, researchers in The Netherlands turned to liposomes, microscopic vesicles used to deliver drugs or genetic material directly into a cell. They chose RGD peptide liposomes to deliver a dose of dexamethasone phosphate (DEXP) to VECs at the site of inflammation in rats with experimental arthritis. The results, presented in the April 2006 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), indicate the promise of targeted liposomal therapy for rheumatoid arthritis patients.

RGD peptide was selected for targeting of the liposomes based on its high chemical stability and its high affinity for proteins expressed on angiogenic VECs At sties of inflammation. To create a disease sample, rats with adjuvant-induced arthritis (AIA) and rats or mice were injected with a lipopolysaccharide (LPS)-induced inflammation were used. After disease onset, generally 12 days after the inductions, the rats were randomly divided to receive treatment. One group received a single intravenous injection of 1 milligram of DEXP encapsulated in targeted RGD peptide-exposing polyethylene glycol liposomes (RGD-PEG-L). Another group was injected with the same dosage of DEXP encapsulated in non-targeted PEG liposomes. A control group was
'"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
29-Mar-2006


Page: 1 2

Related medicine news :

1. Fighting the battle against disease - Leeds researchers take on the world
2. Pathway links inflammation, angiogenesis and breast cancer
3. Fat protein cuts blood vessel inflammation, may help heart, Jefferson scientists find
4. Brain inflammation may be friend, not foe, for Alzheimers patients
5. Blood inflammation plays role in Alzheimers disease
6. New insights into chronic inflammation and atherosclerosis
7. New prevention, treatment methods for patients with painful bowel inflammation
8. Gene transfer using mutant form of good cholesterol cuts vascular plaque and inflammation
9. Depressed patients experience excessive inflammation during stressful situations
10. Resolvin E1 protects against inflammation and bone loss
11. Research shows fat fuels inflammation killer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Fighting inflammation with targeted liposomal therapy

(Date:6/19/2013)... 2013 In honor of women everywhere, ... providing information that women can use to improve their ... women should pay close attention to their health, as ... changes a woman’s body undergoes while pregnant can increase ... says Dr. Ray Workman, a leading vein doctor at ...
(Date:6/19/2013)... Washington, DC (PRWEB) June 19, 2013 ... experiment in the history of managed care. As ... find coverage through the new state-based and federally ... requirements for essential health benefits, and examples of ... some states, industry-leading health business information publisher Atlantic ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Scott Tischler of ... curb this swim suit season. , 1.    The very first thing ... big tall glass of ice cold water. The body is ... water. This will keep the body hydrated and will also ... body has to raise the temperature of the water to ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As Mirena ... LLP highlights a recent news story from an NBC ... effects of the hormone-based contraceptive device. The Rottenstein Law ... to file Mirena lawsuits and who are ... The U.S. Food and Drug Administration has logged more ...
(Date:6/19/2013)... Transvaginal mesh lawsuits are moving along in the New ... how to handle evidence in the C.R. Bard lawsuits, specifically ... components removed from patients. The Rottenstein Law Group LLP maintains ... about the device and a guide on how to file ... the medical facilities that currently hold them and are to ...
Breaking Medicine News(10 mins):Health News:Novant Health Vein Specialists Promotes Women’s Health with Social Media Campaign 2Health News:New Special Report Provides Comprehensive Overview of New Health Insurance Exchange Marketplaces 2Health News:Rottenstein Law Group LLP Comments on News Reports of Mirena IUD Side Effects 2Health News:Transvaginal Mesh Lawsuit News: NJ Mesh Consolidation Cases Moving Along, Rottenstein Law Group LLP Reports 2
(Date:6/18/2013)... , June 18, 2013  Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a general corporate update in conjunction ... on Tuesday, June 25 at 2:10 p.m. Pacific Time in ... for the meeting is as follows: 2:00 p.m. – 2:10 ... as of April 26, 2013) 2:10 p.m. – 3:15 p.m. ...
(Date:6/17/2013)... WASHINGTON , June 17, 2013 ... ) presented additional data today at ENDO 2013, ... demonstrating that tasimelteon can entrain (synchronize) both melatonin ... potential to reset the master body clock and ... Non-24-Hour Disorder (Non-24).  The SET (Safety and Efficacy ...
(Date:6/17/2013)... June 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... it has filed a preliminary prospectus supplement to its effective ... a similar filing with securities regulatory authorities in each of ... with a public offering of its common shares to raise ... The Company will also grant to the underwriters of the ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4
Cached News: